Activation of human lung semicarbazide sensitive amine oxidase by a low molecular weight component present in human plasma  by Dalfó, E. et al.
www.bba-direct.com
Biochimica et Biophysica Acta 1638 (2003) 278–286Activation of human lung semicarbazide sensitive amine oxidase
by a low molecular weight component present in human plasma
E. Dalfo´a, M. Hernandeza, J.M. Lizcanoa, K.F. Tiptonb, M. Unzetaa,*
aDepartament de Bioquı´mica i Biologı´a Molecular, Institut de Neurociencies, Facultat de Medicina, Universitat Auto´noma de Barcelona,
08193 Bellaterra, Barcelona, Spain
bBiochemistry Department, Trinity College, Dublin 2, IrelandReceived 7 January 2003; received in revised form 2 May 2003; accepted 18 June 2003Abstract
Semicarbazide-sensitive amine oxidase (SSAO) encodes a wide family of enzymes named E.C.1.4.3.6 [amine:oxygen oxidoreductase
(deaminating) (copper containing)] that metabolises primary aliphatic and aromatic amines. It is present in almost all vascularised and
nonvascularised mammalian tissues, and it is also present in soluble form in plasma. SSAO appears to show different functions depending on
the tissue where it is expressed. Here we describe, for the first time, the activation of the SSAO from human lung by human plasma. The
extent of activation was greater when the human plasma came from diabetic and heart infarcted patients. A kinetic mechanism of such effect
is proposed. The activation was lost after the plasma was dialysed, indicating a low molecular weight component (MW <3800 Da) to be
responsible. The activator component is heat stable and resistant to proteolysis by chymotrypsin and trypsin and also resistant to perchloric
acid treatment. However, treatment with 35% formic acid, completely abolished activation, suggesting involvement of lipid material. The
possibility of that lysophosphatidylcholine (LPC), an amphiphilic phospholipid derived from the phosphatidylcholine, the major component
in plasma accumulated in pathological conditions, was studied. LPC was shown to behave as a ‘‘competitive activator’’ of human lung SSAO
at concentrations below its critical micellar concentration (CMC value = 50 AM). Thus LPC may be a component of the SSAO activatory
material present in human plasma.D 2003 Elsevier B.V. All rights reserved.Keywords: Semicarbazide-sensitive amine oxidase; Activation; Plasma component; Lysophosphatidylcholine1. Introduction
Several amine oxidising enzymes are inhibited by semi-
carbazide. These include beef and sheep plasma spermine
oxidase, plasma amine oxidase, lysyl oxidase, diamine
oxidase and a tissue-bound amine oxidase. All are inhibited
by semicarbazide as a result of the presence of a carbonyl-
group-containing cofactor. However, the term semicarba-
zide-sensitive amine oxidase (SSAO) is generally used to
describe those enzymes that catalyse the oxidative deamina-
tion of aliphatic and aromatic primary amines. They are
included in the classification as E.C.1.4.3.6 [amine:oxygen
oxidoreductase (deaminating) (copper-containing)]. Semi-
carbazide is frequently used to distinguish the SSAOs from
the monoamine oxidase (MAO) [amine:oxygen oxidoreduc-0925-4439/03/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
doi:10.1016/S0925-4439(03)00094-2
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E-mail address: Mercedes.Unzeta@uab.es (M. Unzeta).tase (deaminating)(flavin-containing)], E.C.1.4.3.4, that is
sensitive to acetylenic inhibitors such as clorgyline and l-
deprenyl, but it is not affected by semicarbazide. The
substrate specificity of MAO and SSAO overlap to some
extent but, whereas MAO catalyse the oxidative deamination
of primary, secondary and tertiary amines, the activity of
SSAO appears to be restricted to primary amines. Methyl-
amine, which arises from the metabolism of adrenaline,
lecithin, sarcosine, and creatinine, is metabolised by SSAO
from many sources [1,2] and it has been proposed to be a
physiological SSAO substrate, since it is not oxidised by
MAO. Both enzymes catalyse the oxidative of deamination
primary amines to the corresponding aldehyde, ammonia,
and hydrogen peroxide, according to the overall reaction:
RCH2NH2 þ O2 þ H2O Z RCHOþ NH3 þ H2O2
SSAO is tightly associated with membranes in several
mammalian tissues and also occurs as a soluble form in
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high activity in blood vessels and appears associated with
smooth muscle cells [5,6]. Vascular smooth muscle cells in
culture have been reported to secrete a soluble form of
SSAO [7] that may represent the origin of the plasma
enzyme. SSAO activity has been also found in nonvascular
cell types [8], dental pulp [9], chondrocytes [10] and in
adipocytes, from rat white and brown fat [11]. Despite its
wide tissue distribution in human tissue [12], the physio-
logical role of SSAO is still far from clear. SSAO present in
the microsomal fraction of human and bovine lung [13,14]
may be important in the metabolism of inhaled volatile
amines [15]. The SSAO located in the plasma membrane
may act as a scavenger of circulating toxic amines. It
appears that this enzyme is also involved in the control of
cellular activities mediated by H2O2 [16]. It has been
recently reported that SSAO colocalises with the GLUT4
glucose transporter in the endosomal compartment in rat
adipocytes and that SSAO-catalysed substrate oxidation
results in a marked stimulation of glucose transport, mim-
icking the insulin effect [17].
A vascular-adhesion protein VAP-1, present in endothe-
lial cells, has been shown to have an identical amino acid
sequence to SSAO [18]. Because VAP-1 is induced in
inflammation and is involved in lymphocyte migration to
lymphoid organs, a new physiological role in cellular
trafficking has been proposed for SSAO [19]. However,
the VAP-1 expressed in smooth muscle cells has been
reported to be structurally and functionally distinct from
VAP-1 present in endothelial cells and not support binding
to lymphocytes [20].
SSAO activity appears to be altered in several patholog-
ical conditions. Changes in plasma SSAO activity have
been reported in fibrotic liver and in patients suffering from
burns [5]. SSAO from human plasma is elevated in con-
gestive heart failure [21]. A decreased membrane-bound
SSAO activity has been reported in chemically induced rat
breast tumours [22]. Plasma SSAO is also increased in
streptozotocin-induced diabetic rats [23] and also in patients
suffering from diabetes [24]. Cardiovascular complications
and retinopathy are serious consequences of diabetes
[25,26], and it has been suggested that toxic metabolites
arising from the SSAO-catalysed oxidative deamination of
aminoacetone and methylamine may be a contributing
factor. The formaldehyde generated by SSAO in vascular
tissues could be a potential risk factor for stress-related
angiopathy [27].
In the present study, we describe for the first time the
activation of the membrane-bound SSAO from human lung,
by a low molecular weight phospholipid-like component
present in human plasma. The levels of this activator
appeared to vary in different pathological conditions, in-
creasing during acute phase reactions. Lysophosphatidyl-
choline (LPC) has been shown to activate the SSAO,
suggesting that it may be a component of this plasma
activator.2. Materials and methods
2.1. Materials
Superdex 200 HR was purchased, as a pre-packed
column, from Pharmacia. Centricon-10 miniconcentrators
and XM-50 ultrafiltration membranes were from Amicon.
The radioactive substrates [7-14C]benzylamine hydrochlo-
ride (specific activity 57 mCi/mmol) and [14C]methylamine
(779 ACi/mg) were obtained from Amersham International.
All other reagents were from Sigma-Aldrich.
2.2. Human plasma
The Ethical Committee of the Autonomous University of
Barcelona has approved the experimental protocol used for
human samples. Human plasma samples were obtained from
the Hospital General de la Vall d’Hebron, Servei d’Hema-
tologia, Barcelona, Spain, and stored at  20 jC until use.
Samples of pathological human plasma were obtained from
the Biochemical Analysis Unit the Hospital General de la
Vall d’Hebron, Barcelona, Spain.
2.3. Preparation of human lung microsomes
Human lung was obtained from the Servicio Anato´mico
Forense del Hospital Clı´nico Provincial de Barcelona, Spain,
transported immediately to the laboratory and stored at  20
jC until use. After removing the connective tissue, the lung
was weighed, chopped into small pieces with scissors and
washed extensively with saline (0.9%, w/v, NaCl) to elim-
inate blood as a potential source of contaminating plasma
amine oxidase. The tissue was then homogenised in 10
volumes (w/v) of 10 mM Tris/HCl buffer, pH 7.2, containing
0.25 M sucrose, in a Waring blender, and filtered through
two layers of cheesecloth. The homogenate was subjected to
differential centrifugation and the microsomal fraction was
obtained by adding 10 mM CaCl2 to the post-mitochondrial
supernatant and centrifuging as previously described [14].
The final microsomal pellet was resuspended in 50 mM
potassium phosphate buffer, pH 7.2. The protein concentra-
tion was adjusted to 10 mg/ml and samples were stored in
aliquots at  20 jC until required. The resulting preparation
was referred as crude microsomes.
2.4. Concentration of plasma and activation experiments
Plasma was thawed at 37 jC and 200 ml aliquots were
filtered through an Amicon ultrafiltration cell equipped with
XM-50 membranes (50 kDa cutoff). The filtrate (40 ml) was
recovered and filtered again, through a Centricon-10 ultra-
filtration unit. The final filtrate was concentrated four to five
times by lyophilisation and resuspension in 50 mM potas-
sium phosphate buffer, pH 7.2. The filtrate containing the
activator was then used for the proteolytic, formic acid and
perchloric acid treatments, as described below.
iophy2.5. Enzyme assays
SSAO activity in human lung microsomes was deter-
mined radiochemically at 37 jC, by the method of Fowler
and Tipton [28], using [14C]benzylamine (3 mCi/mmol) 20
AM as substrate. The reaction mixture contained SSAO
enzyme and substrate in a total volume of 225 Al of 50
mM potassium phosphate buffer pH 7.2. The reaction was
stopped by the addition of 100 Al of 2 M citric acid.
Radioactive-labelled products were extracted into toluene/
ethyl acetate (1:1, v/v) containing 0.6% (w/v) 2,5-dipheny-
loxazole (PPO), before liquid scintillation counting. Be-
cause of the low SSAO activity present in human plasma,
activities were determined in this case by the same method
described above but using 100 AM benzylamine as substrate
and pH 9 in 20 mM Tris–HCl buffer.
SSAO activity in human lung microsomes was deter-
mined towards 100 AM [14C]methylamine (1 mCi/mmol) as
described by Precious et al. [29]. The reaction was carried at
37 jC in a final volume of 100 Al of 50 mM potassium
phosphate buffer pH 7.2, and was stopped by cooling the
tubes in an ice bath. The reaction product, [14C]formalde-
hyde, was separated from any unchanged amine by passage
through a 1 ml Amberlite C6–50 (carboxylic form) column.
Six milliliters of Bray solution was added to the column
eluate before liquid scintillation counting.
When required, SSAO activity was inhibited by preincu-
bating samples for 30 min at 37 jC with 1 mM semi-
carbazide, a procedure that did not affect MAO activity.
MAO-B and MAO-A activities were selectively inhibited
by preincubation, under the same conditions with 1 AM l-
deprenyl and 1 AM clorgyline, respectively. Preincubation
with 1 mM clorgyline was used to inhibit the total MAO
activity, without affecting that of SSAO. Time course assays
were used to ensure that initial rates of the reaction were
determined, and the proportionality of the initial rates to
enzyme concentration was also established in each case.
Kinetic parameters were calculated by nonlinear regression
analysis, using the computer program Graph-Pad Prism.
2.6. Treatment of plasma with formic acid, perchloric acid
or Triton X-100
One hundred microliters of 0.4 M perchloric acid was
added to 200 Al of lyophilised human plasma. The mixture
was stirred for 5 min and then centrifuged at 13,000 g for
10 min. The supernatant was neutralised with 1 M NaOH,
and stored at 4 jC until assay for its ability to activate human
lung microsomal SSAO. The same experimental procedure
was used for formic acid treatment, except that the acid
concentration was 1.2 M. Samples of crude microsomes
were mixed with Triton X-100 at a final concentration of
0.6% (w/v). After stirring at 4 jC for 30 min, samples were
centrifuged at 105,000 g for 1 h. The resulting pellet and
supernatant were collected and the protein content and
SSAO activity were determined in each fraction.
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For peptidase treatment, 300 Al of filtered and concen-
trated human plasma was incubated overnight at 37 jC with
100 Al of either trypsin or chymotrypsin, each at 1 mg/ml, in
0.1 M ammonium bicarbonate, pH 9. In controls, the
peptidases were replaced by 100 Al of 0.1 M ammonium
bicarbonate. After this proteolytic treatment, its activating
effect was assayed on human lung SSAO.
Additional experiments were performed to confirm the
lack of effect of the peptidase treatment on the SSAO
activating component from plasma. Filtered and concentrat-
ed human plasma was chromatographed on Superdex-
200HR-FPLC, previously equilibrated with 0.1 M ammo-
nium bicarbonate buffer, pH 9. Fractions (0.5 ml) containing
the activator were incubated 20 h at 37 jC with 100 Ag of
either trypsin or chymotrypsin and then assayed for their
abilities to activate human microsomal SSAO, as described
above. In the heat-treatment studies, samples of plasma were
incubated at 100 jC for 30 min, before cooling on ice and
assessing its activation effect towards human lung SSAO, as
described above.
2.8. Estimation of the Mr of the activator
Filtered and concentrated human plasma was chromato-
graphed on Superdex-200HR-FPLC, equilibrated with 50
mM potassium phosphate buffer, pH 7.2. Fractions (0.5 ml)
were collected and assayed for their ability to activate
human microsomal SSAO, as described above. The approx-
imate molecular weights of the eluted material were deter-
mined by reference to a calibration curve constructed from
different molecular weight (kDa) markers.
2.9. Thin layer chromatography
Concentrated human plasma samples were extracted for
chromatography of lipids by the following procedure. Chlo-
roform/methanol, 1.2 ml, was added to 0.25 ml of concen-
trated human plasma. The sample was allowed to stand for
10 min at room temperature and 0.5 ml chloroform and 0.5
ml of 0.25 M HCl were added. The mixture was stirred
vigorously and centrifuged 2500 rpm for 5 min. The
aqueous and organic phase were separated and evaporated
under an atmosphere of N2. The aqueous phase was neu-
tralised with 1 M NaOH and then assayed for its activation
effect towards human lung microsomes. The organic phase
pellet was resuspended in 20 mM potassium phosphate
buffer, pH 7.2, and applied to a silica-gel TLC plate. The
TLC was developed with chloroform/methanol/acetone/
acetic acid/water (50:10:20:10:5), and stainedwith ninhydrin.
2.10. Protein quantification
Protein was measured by the method of Bradford [30],
using bovine serum albumin (BSA) as standard.
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Data were expressed as meanF S.D. of the values from
the number of experiments as indicated in the corresponding
figures. For multiple comparisons, one-way ANOVA test by
the addition of Dunnett’s test, was used. Significance was
accepted when PV 0.01.
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human plasma at different pH. SSAO activities were performed in 50 mM
phosphate buffer, pH 7.2, or in 20 mM Tris–HCl pH 9, towards 100 AM
benzylamine as substrate. In both cases, a preincubation for 30 min with 20
Al of FLHP was done to study the activation effect. The data are expressed
in percentage of activation versus control SSAO activitiesF S.D. of two
independent experiments performed in triplicate. (a) Human plasma; (b)
human plasma + FLHP; (c) human lung microsomes; (d) human lung
microsomes + FLHP; (e) SSAO activity present in FLHP.3. Results
3.1. Activation of SSAO from human lung by human plasma
Human lung microsomes were preincubated with differ-
ent amounts of human plasma, for 30 min at 37 jC and the
reaction started by adding either methylamine (100 AM) or
benzylamine (20 AM), as SSAO substrates. Fig. 1 shows the
percentage increase in SSAO activity with respect to con-
trols (taken as 100%) measured in absence of human
plasma. The activation was dose-dependent in both cases,
but the effect depended upon the substrate used in the assay;
30 Al of human plasma caused a 5-fold activation of the
SSAO activity towards the physiological substrate methyl-
amine, whereas the activation effect on benzylamine was
only 3-fold.
This activation was not simply an additive effect of the
soluble SSAO activity present in human plasma, since this
activity was too low at pH 7.2 (1.253F 0.076 pmol/min/mg
protein, n = 6) to account for the observed activation of
the human lung SSAO, which had a specific activity of
1893.8F 150 pmol/min/mg protein (n = 6) at this pH, to-
wards benzylamine as substrate. The activities of both the
plasma and lung enzymes were higher at pH 9.0, 2.598F
0.14 pmol/min/mg protein (n = 6) and 3146.8F 97.5 pmol/
min/mg protein (n = 6), respectively, but no activation was
observed at that pH value.Fig. 1. Activation of human lung microsomal SSAO by human plasma.
Human lung microsomes were preincubated with different amounts of
filtered and lyophilised human plasma (FLHP) for 30 min, before starting
the reaction by adding 100 AM methylamine or 20 AM benzylamine as
substrates.MAO-A and MAO-B are present in the human lung
microsomal fraction, and because benzylamine is also a
MAO-B substrate, the activation was determined after
preincubation of human lung microsomes with 1 mM
clorgyline, in order to fully inhibit MAO. Activation was
still observed under these conditions, indicating that MAO
is not involved in this effect. When the activity was deter-
mined towards 5-hydroxytryptamine, a specific MAO-A
substrate, no activation by plasma was observed, confirming
that this MAO isoform is not affected by this plasma
component. However, when lung microsomal SSAO was
inhibited with 1 mM semicarbazide, no activation effect was
observed by human plasma, confirming that SSAO was the
only amine oxidase present in human lung that is activated
by the plasma component.
3.2. Activation of membrane-bound SSAO and plasma
SSAO is pH dependent
The activating effect of the concentrated low molecular
weight plasma component was determined towards human
lung SSAO, and human plasma, at two different pH values
(see Fig. 2). Activation was observed only at pH 7.2, but no
effect was observed at pH 9 in any case. Whereas plasma
SSAO was activated 2.3-fold under these conditions, the
maximum activation in SSAO from human lung was only
1.7 times. The lack of agreement between these data and
those reported in Fig. 1 might be explained in terms that
different benzylamine concentrations have been used in
each experiment. In that case, SSAO activity was assayed
towards 20 AM benzylamine whereas in this experiment,
100 AM benzylamine has been used to detect SSAO in
human plasma, which is very low comparing with human
lung.
Fig. 4. Kinetic behaviour of the activating effect by human plasma on the
human lung SSAO. Double-reciprocal plot of SSAO activation towards
benzylamine as substrate (0.025–0.5 mM). Human lung microsomes were
preincubated with different amounts of FLHP (10–50 Al) for 30 min,
before starting the reaction by adding benzylamine.
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pathological subjects
Activation was studied in the presence of human plasma
from subjects suffering different pathologies. The micro-
somal preparation was preincubated with 50 Al plasma
sample in 50 mM potassium phosphate buffer pH 7.2,
before the SSAO activity was measured towards benzyl-
amine (20 AM) as substrate. Fig. 3 shows the increase of
human lung SSAO activity after incubation with plasma
from subjects with different pathologies. Plasma from
patients recovering from burns gave an activating effect that
was similar to that observed with healthy human plasma
(about 3-fold activation), whereas the activation was about 4-
fold when plasma from diabetes, heart infarcted and burns
patients also suffering heart infarction were assayed.
3.4. Some characteristics of the human plasma activatory
component
Samples of human plasma were dialysed overnight
against 50 mM potassium phosphate buffer, pH 7.2, at 4
jC. A 50 Al sample of the dialysed plasma were assayed for
their ability to activate human lung SSAO, using benzyl-
amine (20 AM) as substrate. No activation effect was ob-
served, suggesting that the factor responsible for the
activation could be a low molecular weight component that
was lost after dialysis.
The plasma component responsible of the activation was
heat stable, since its ability to activate was not affected after
heating the plasma at 100 jC for 30 min.
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pathological human plasmas. Human lung microsomes were preincubated
for 30 min with 50 Al of human plasma from healthy subjects or with
plasma from different pathologies, and the activation effect was determined
towards benzylamine (20 AM) as substrate at pH 7.2. C = human lung
SSAO activity; control (n= 3); N =C+ healthy plasma (n= 5); B =C+ burn
plasma (n= 4); D =C+ diabetic plasma (n = 6); I = C + heart infarcted
plasma (n= 5); B + I =C+ burns and heart infarcted plasma (n= 4). Data
are meanF S.D. (*) PV 0.01 One-way ANOVA test by the addition of the
Dunnett’s test versus N.In order to investigate whether the specific lipid envi-
ronment of the membrane-bound enzyme SSAO from
human lung microsomes might mediate the activating effect,
it was solubilised with 1.2% Triton X-100 as previously
described. This treatment did not affect the activation of the
enzyme by the human plasma component, suggesting that
interactions with the enzyme itself are involved, rather than
with the lipid surrounding. Treatment of human plasma with
the proteolytic enzymes, trypsin and chymotrypsin, did not
reduce its activating effect. Furthermore, the activatory
component was not precipitated by 1.2 M perchloric acid.
Taken together, all these results suggest that the activatory
component is unlikely to be a protein, although the possi-
bility that a small peptide might be responsible for the
activation cannot be excluded.
Treatment of human plasma with 35% formic acid
completely abolished the activating effect, suggesting that
the component(s) responsible for activation might be either
a lipid or a sugar component present in human plasma.
However, our latest results on the inhibitory effect on tissue-
bound SSAO, by amino sugars, prompted us to discard the
latest possibility (manuscript accepted for publication in
BBA).
3.5. Kinetic studies
Initial-rate kinetic studies of the effects of the quantity of
human plasma on the extent of activation of human lung
SSAO showed the activation to be ‘‘competitive’’ (Fig. 4)
with respect to benzylamine. Thus, the Km values decreased
as the amount of human plasma was increased, without any
significant effect on the limiting velocity (Vmax). These
results indicate that the activating factor interacts with the
Fig. 5. Estimation of the molecular weight of the human plasma activator.
(A) FLHP was chromatographed through a Superdex-200HR column
connected to an FPLC system. Fifty-microliter aliquots of eluted fractions
were preincubated with 25 Al human lung microsomes for 30 min before the
reaction was started by adding 20 AM benzylamine. (B) Calibration of the
Superdex-200HR column using the following molecular weight (kDa)
markers: horse spleen apoferritin (443); yeast alcohol dehydrogenase (150);
bovine serum albumin (66); erythrocyte carbonic anhydrase (29); and horse
cytochrome c (13).
E. Dalfo´ et al. / Biochimica et Biophysica Acta 1638 (2003) 278–286 283membrane-bound SSAO in such a way as to increase the
apparent first-order rate of combination of benzylamine with
the enzyme (indicated by Vmax/Km) without affecting the
limiting rate of catalysis (indicated by Vmax).
This nonessential, or partially competitive, activation can
be represented by the scheme
where the binding of the activator, A, to the enzyme results
in the generation of a new species EA with a higher affinity
for substrate binding (KSV<KS and hence KaV<Ka).
If one assumes that all dissociation steps are at thermo-
dynamic equilibrium, the rate equation is quite complex
[31].
m¼ V
1þ KS½S 
1þ ½A
Ka
1þ ½A
Ka
 KS
KSV
0
BB@
1
CCA
¼ V
1þ KS½S 
1þ ½A=Ka
1þ ½A=KaV
 
This predicts that the variation of the apparent slopes of
the lines in Fig. 4 upon the activator concentration will be
nonlinear, decreasing from an initial value of KS/V when the
activator concentration is zero to a finite value limited by KSV/
V. The apparent KS value (KS
app.) in the presence of activator
will be:
K
app:
S ¼
KSð1þ ½AKaÞ
1þ ½AKS=KaKSV ¼
KSð1þ ½A=KiÞ
1þ ½A=KaV
Hence, if the apparent values of KS in the presence of the
activator are subtracted from the value in its absence, the
values (DKS
app.) will be a rectangular hyperbolic function of
the activator concentration, according to the relationship
2K
app:
S ¼ KS 
KSð1þ i=KiÞ
ð1þ i=KiVÞ
¼ KS  i=KiV KS  i=Ki
1þ i=KaV
Fitting the data by nonlinear regression gave a value for KaV
of 20.1F 4.4 Al plasma and a maximum degree of activa-
tion, with benzylamine as substrate, of 2.74F 0.24-fold.
3.6. Determination of the apparent molecular weight of the
plasma activatory component
The activating factor was concentrated by filtering the
human plasma thorough an Amicon ultrafiltration cell
equipped with XM-10 membranes (110 kDa cutoff).
The filtered activator was then lyophilised and taken upin 0.1 M ammonium bicarbonate buffer pH 9, to give a
further concentration of 4–5-fold. This was then gel-
filtered by FPLC, through a column of Superdex-
200HR equilibrated with the same buffer. Fractions of
0.4 ml were collected and each was assayed to determine
the activatory effect towards the microsomal SSAO at pH
7.2. As shown in Fig. 5, the activating material was
concentrated in the major, symmetrical peak eluted from
the column. This corresponded to a molecular weight of
about 3800 Da.
3.7. Activating effect by LPC
These results indicated that the component(s) responsible
for the activation of human lung membrane-bound SSAO
was of low molecular weight. Furthermore, the results
obtained by TLC suggest that the activating plasma com-
ponent migrated with the same Rf value as lysophoshati-
Fig. 7. Kinetic behaviour of the activation of human lung SSAO by LPC.
Double-reciprocal plot of SSAO activation by LPC towards benzylamine as
substrate. Human lung microsomes were preincubated in the absence and
presence of 40 AM LPC for 30 min, before the assay of the activity towards
benzylamine (0.025–0.5 mM) as substrate.
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possible activation of membrane-bound SSAO by LPC. Fig.
6 shows the effects of LPC at two different concentrations,
40 AM, below its critical micellar concentration (CMC
value: 50 AM) and at 100 AM LPC, above its CMC value.
Activation by LPC was higher at the lower concentration
used (40 AM), resulting in a 140% increasing of the basal
activity level, whereas the corresponding activation ob-
served with 100 AM LPC was only 120%. Micelles are
not formed at the lower concentration of LPC used since it is
below its CMC value. Thus, the observed activation at 40
AM LPC is not a result of membrane disruption by micelles.
These results are in agreement with those observed with
microsomes solubilised with Triton-X-100, in which the
activation effect by human plasma was maintained, indicat-
ing that this effect was not mediated by membrane compo-
nents, but rather owing to a direct effect on the SSAO
enzyme itself.
The total LPC concentration in human plasma from
healthy subjects has been determined to be about 0.171
mmol/l and this value is increased to 0.289 mmol/l in some
pathologies, such as acute asthma [32]. Thus, the LPC
concentrations used in the present work is below those that
may be encountered in some disease states. Thus, a greater
activating effect on the tissue-bound SSAO may occur in
some diseases, although the effects of LPC binding to
plasma components have yet to be evaluated.
3.8. Kinetic studies on the activation by LPC
The kinetic parameters of the human lung microsomal
SSAO were determined in the absence and in presence of
different concentrations of LPC. The double-reciprocal plots
(Fig. 7) showed the activation to be ‘‘competitive’’, since
the Km value was decreased without significant alteration of
Vmax. This behaviour is similar to the kinetic behaviourFig. 6. Activator effect of LPC on microsomal human lung SSAO. Human
lung microsomes were preincubated with 40 or 100 AM LPC before adding
20 AM benzylamine as substrate. Data are meanF S.E. (**) P < 0.01 One-
way ANOVA with Dunnett’s post test versus Control.observed in the activation of human lung SSAO by human
plasma.4. Discussion
Semicarbazide-sensitive amine oxidase is present in al-
most all mammalian tissues; however, its physiological role
is still far from clear. It has been reported that factors present
in human plasma can modulate MAO activity in platelets.
This enzyme has been shown to be inhibited by plasma from
schizophrenic patients [33], whereas others have reported
MAO to be activated by human plasma in a substrate-
selective way [34] and have suggested that the activator is
a phospholipid-like molecule. Recently, Whalund et al. [35]
reported that human platelet MAO is activated by a high
molecular weight fraction (Mr>50.000) present in human
plasma. Buffoni et al. [36] described the presence of a high
Mr (200.000) inhibitor of SSAO in human plasma and
suggested that it might account for the low activity of this
enzyme under nonpathological conditions.
Some authors have described that inhibition of MAO can
modulate the behaviour of SSAO, by an as yet unknown
mechanism [37]. However, this is the first report on the
activation of human tissue-bound SSAO by a human plasma
component, without effect on either MAO-A or MAO-B.
Concentrated samples of this component, which appears to
have a low molecular weight (Mr 3800), also activated
human plasma SSAO. The extent of activation appeared
to be different when plasma samples from subjects with
different disease states were assayed, which may reflect
variations in the concentration of the activatory material
under such conditions.
E. Dalfo´ et al. / Biochimica et Biophysica Acta 1638 (2003) 278–286 285Since the properties of this activatory material were
consistent with the involvement of a phospholipid, we
investigated the effects of LPC on the activity of the
enzyme. LPC is an amphiphilic phospholipid that is derived
from phosphatidylcholine, the major component in plasma,
that is formed during the oxidation of low-density lipopro-
tein (LDL) [38,39]. LPC is secreted directly by the liver [40]
and is present in large amounts in plasma, about (5–20%) of
total phospholipids, depending on the mammalian species
[41]. Furthermore, it can be accumulated in pathological
conditions such as atherosclerosis and ischemia [42]. It has
been reported that LPC regulates a variety of cellular
functions, such as the activation of protein kinase C
(PKC), the increase of cyclic AMP through G-protein path-
ways [43] and the increase of intracellular Ca2 + levels. It has
been also reported that LPC induces NFkB-binding activity
[44] and stimulates growth factor release, from vascular
smooth muscle cells [45]. However, LPC can induce injury
in a variety of cell types by a process that appears to involve
oxidative stress [46]. In this context, the hydrogen peroxide
formed in the SSAO-catalysed reaction has been suggested
to contribute to oxidative tissue damage under pathological
conditions (see Refs. [3,24]) and thus the activation of
membrane-bound SSAO by LPC might exacerbate LPC-
induced tissue damage.
LPC does resemble the endogenous plasma SSAO
activator, in behaving as a partial ‘‘competitive activator’’
of the enzyme. However, the extent of activation by this
phospholipid at concentrations below its critical-micellar
concentration was lower than that observed with the plasma
samples. One possible explanation could be that the LPC
concentration used in these experiments is below that
present in healthy controls (0.171 mmol/l) and in some
disease states, such as acute asthma (0.289 mmol/l) [47].
However, other components present in plasma may also
contribute to the activatory effect. In this context, it has
been recently described that SSAO appears to be localised
with the scavenger lipoprotein receptor, CD36, in the
caveolae of adipocytes and perhaps some other cell types
[48]. Further experimental work must be done in order to
identify the SSAO activatory molecules present in human
plasma, and how their levels are altered in different disease
states, that are known to result in changes of SSAO
activity. Further studies of this activating effect should be
relevant to our understanding of the significance of changes
in SSAO activity, in response to different pathological
conditions.Acknowledgements
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